Lucence has a proprietary sequencing technology was first invented in Singapore to enable non-invasive cancer treatment selection via ultrasensitive liquid biopsy. This technology has now been brought to the world stage via its flagship blood test, LiquidHALLMARK - with impressive milestones already reached.

This technology has also now been applied to a further breakthrough core product, LucenceINSIGHT. Launched in Asia in 2023, it uses these liquid biopsies to detect cancer earlier, giving people a real chance to discover and treat the disease. LucenceINSIGHT will help deliver better outcomes on an individual patient level, and lower the rate of avoidable cancer deaths. On a systemic level, it will help reduce the burdens of cancercare on health systems across the world, often confronting ageing populations.